Recently, we isolated cDNAs for the TXA2 receptor (15, 16) and the EP1 (17), the EP2 (18), and the EP3 (19, 20) subtypes ofthe PGE receptors by homology screening. These studies revealed that prostanoid receptors constitute a subfamily within the rhodopsin-type, G protein-coupled receptor superfamily (21), and they enabled us to identify highly conserved amino acid sequences in these receptors. To clone the cDNAs for other prostanoid receptors, we have carried out reverse transcription polymerase chain reaction (RT-PCR) studies based on such motifs and have successfully amplified three cDNAs encoding sequences homologous to prostanoid receptors. Of these three, one has been identified as being part of the PGF receptor cDNA (22) and another as being part of the PG1 receptor cDNA (23). The third, unidentified, cDNA showed a high degree ofsequence similarity to the PGI receptor (23) and to the EP2 subtype of the PGE receptor (18). We postulated that the cDNA may code for a member ofthe relaxant prostanoid receptor family. Here, we report the primary structure of this mouse cDNA and its gene.t We also describe the identification ofthe gene product MATERIALS AND METHODS Lgands. PGD2, PGE2, PGF2a, and STA2 (9,11-epithio-11,12-methano-TXA2) were kindly provided by Ono Pharmaceuticals (Osaka). BW 245C [5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin] and BW A868C
Prostanoids such as the prostaglandins (P s) and thromboxane (TX) are cyclooxygenase metabolites of arachidonic acid (1) and exert a variety ofbiological activities to maintain local homeostasis in the body (2) . Each of these compounds acts through its own specific receptor, which is coupled to the regulatory G protein(s) (3) . At least seven pharmacologically distinct prostanoid receptors have been identified (4) : the TXA2 receptor, the EP1, EP2, and EP3 subtypes of the PGE receptor, the PGF receptor, the PGI receptor, and the PGD receptor. Of these, the EP2 subtype ofthe PGE receptor, the PGI receptor, and the PGD receptor have been classified as relaxant prostanoid receptors (4); they preferentially activate adenylate cyclase in.their second messenger pathways and produce relaxation in smooth muscle preparations. PGD2 is formed in a number oftissues and cells and produces a variety ofbiological responses (4, 5) . For example, PGD2 acts during platelet aggregation as a negative-feedback regulator (5) , produces relaxation of vascular and nonvascular smooth muscle (6) (7) (8) , and modifies autonomic as well as sensory nerve functions (9, 10) . It is also released by mast cells and cells of the macrophage lineage to play a role during immunologic reactions (11) (12) (13) . Finally, PGD2, synthesized in the brain, has been proposed to be a physiological regulator of sleep (14) .
Recently, we isolated cDNAs for the TXA2 receptor (15, 16) and the EP1 (17) , the EP2 (18) , and the EP3 (19, 20) subtypes ofthe PGE receptors by homology screening. These studies revealed that prostanoid receptors constitute a subfamily within the rhodopsin-type, G protein-coupled receptor superfamily (21) , and they enabled us to identify highly conserved amino acid sequences in these receptors. To clone the cDNAs for other prostanoid receptors, we have carried out reverse transcription polymerase chain reaction (RT-PCR) studies based on such motifs and have successfully amplified three cDNAs encoding sequences homologous to prostanoid receptors. Of these three, one has been identified as being part of the PGF receptor cDNA (22) and another as being part of the PG1 receptor cDNA (23) . The third, unidentified, cDNA showed a high degree ofsequence similarity to the PGI receptor (23) and to the EP2 subtype of the PGE receptor (18) . We postulated that the cDNA may code for a member ofthe relaxant prostanoid receptor family. Here, we report the primary structure of this mouse cDNA and its gene. [5, 6, 8, 9, 12, 14, 15 (24) . The resulting plasmid, pdKCR-dhfr-PGc9, was transfected into dhfrdeficient CHO (CHO-dhfr-) cells (25) as previously described (26) . Several 
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PatI Narl 3-kb and 6-kb Xba I restriction fragments that hybridized to the probe. Analysis of these Xba I restriction fragments revealed that the 309-bp sequence corresponding to the 5' segment of PG25 was present in the 3.3-kb fragment. The rest of the PG25 sequence was located in the 6-kb fragment approximately 4 kb away from the upstream sequence (Fig. 1A ). There is a potential translation initiation codon (28) 534 bp upstream of the PG25 sequence in the 3.3-kb fragment. This ATG initiates an open reading frame that codes for an amino acid sequence homologous to the first six transmembrane domains of the prostanoid receptors. The amino acid sequence of the open reading frame in the downstream 6-kb Xba I fragment contains sequence homologous to the seventh transmembrane domain of the prostanoid receptor followed by a short tail sequence and an in-frame stop codon (Fig. 1 A) . The intron has donor and acceptor splice sites compatible with the consensus sequence (29) (Fig. 1B) , and its relative position in the coding sequence is identical to that of the human TXA2 receptor gene (30 (Fig. 1B) . The translated product has a calculated molecular weight of 40,012, and its hydrophobicity profile (31) reveals the presence of seven hydrophobic regions which likely represent transmembrane domains. There are two asparagine residues for putative N-glycosylation: Asn-2 in the N-terminus and Asn-89 in the first extracellular loop. There are also two potential protein kinase C phosphorylation sites (32), Ser-47 and Thr-144, in the first and the second cytoplasmic loops, respectively. In addition, there are eight serines and threonines in the carboxyl-terminal tail, some of which may be sites for phosphorylation by a receptor kinase (21) . Fig. 2 shows the alignment of the deduced amino acid sequence from PGOc9 compared with the sequences from other mouse prostanoid receptors. This analysis revealed that the PGc9 product has 39o and 32% sequence identity over the entire amino acid sequence with the PGI receptor (23) and the EP2 subtype of the PGE receptor (18), respectively, but showed less than 25% amino acid sequence identity with other prostanoid receptors. Thus, the receptor encoded by PGc9, the PGI receptor, and the EP2 subtype of the PGE receptor form a distinct subgroup within the prostanoid receptor family. binding (data not shown). As shown in Fig. 3B (Fig. 4) . This species of mRNA was most abundant in V to CHO-J cells and the ileum, followed by the lung, the stomach and the uterus. I homogenate and
In the lung and ileum lanes, a band of about 7 kb was also beled compounds at apparent. In addition, a band at around 2 kb in ileal RNA was The PGI receptor, the EP2 subtype of the PGE receptor, and the PGD receptor are classified pharmacologically as relaxant prostanoid receptors (4 (Fig. 3A Inset) . Displacement studies showed that the PGD agonist BW 245C (5, 33) (Fig. 3A) . PGE2, PGF2a, and iloprost showed little displacement at 10 AuM, whereas the TXA2 agonist STA2 displaced the binding in a concentration-dependent manner from 100 nM. Parental CHO-dhfr-cells showed no specific [3H]PGD2 DISCUSSION With the PGD receptor described herein, we have now reported the primary structures of all seven pharmacologically defined prostanoid receptors. There are two motifs that are highly conserved in these receptors. The first conserved motif is the QYCPG(T/S)WCF sequence (amino acids 175-183 of the POD receptor) in the second extracellular loop. Although the cysteine residue in this motif (Cys-182) is present in the majority of the G protein-coupled receptors, and is believed to form a disulfide bond with another conserved cysteine residue in the first extracellular loop (Cys-104) (37), the above motif can be found only in the prostanoid receptors. The second conserved motif, RXX(S/T)X(N/I)-XI(V/L)DPW(I/V)(F/Y)(I/L) (amino acids 306-320 of the PGD receptor) is found in the seventh transmembrane domain and contains two charged amino acids, Arg-306 and Asp-315. These conserved residues may interact with the common structure of the ligands for these receptors. Recently, it has been shown that a mutation in this arginine residue in the human TXA2 receptor results in the loss of ligand binding activity (38) .
There are two potential phosphorylation sites for protein kinase C: one in the first cytoplasmic loop and one in the second cytoplasmic loop. The former site is conserved in the EP2 and EP3 subtypes ofthe PGE receptor, whereas the latter is found in the TXA2 and the PGF receptors. In human platelets, phorbol ester treatment abolishes adenylate cyclase activation mediated by the PGD receptor, but spares the response mediated by the PGI receptor (39) . Phorbol ester treatment also attenuates TX agonist-induced GTP hydrolysis in platelet membranes (F.U. and S.N., unpublished observation). These observations indicate that phosphorylation at these sites would affect the coupling of receptor and G protein to produce receptor desensitization.
The PG1 receptor, the EP2 subtype of the PGE receptor, and the PGD receptor have all been classified as relaxant prostanoid receptors (4) . In agreement with this functional classification, their primary structures are more closely related to each other than to the other four prostanoid receptors. In contrast, the TXA2 receptor, the EP1 subtype of the PGE receptor, and the PGF receptor all preferentially raise intracellular calcium and can be functionally classified as contractile prostanoid receptors. They are also more closely related to each other in their primary structure than they are to any ofthe others (22) . Thus, within the prostanoid receptor family, there are two groups of functionally and structurally related receptors. The genomic organization for these receptors may have been conserved during their evolution, because both the human TXA2 receptor gene (30) and the mouse PGD receptor gene contain an open reading frame consisting of two exons separated by an intron at a homologous position.
Northern blotting for the PGD receptor identified a 3.5-kb mRNA in the lung, the gastrointestinal tract, and the uterus. The intestine is one tissue where high PGD synthase activity has been detected (40) . It has also been reported that treatment with PGD2 modifies the chloride transport across the intestinal mucosa (10, 41) . In addition to the tissues identified by RNA blotting, RT-PCR detected the PGD receptor expression in the thymus and brain (M.H. and H. Oida, unpublished observations), suggesting that the PGD receptor expression in these organs may be confined to small region(s) or specific cell(s). PGD2 is one of the major PGs formed in the brain and has been suggested to be a physiological regulator of sleep (14) . The brain-type PGD synthase mRNA has been found to be abundantly expressed in the leptomeninges (42) . PGD2 is formed in the lung under allergic conditions and produces bronchoconstriction (5, 43) . Our results have demonstrated that the PGD receptor preferentially mediates adenylate cyclase activation but not inositolphospholipid breakdown. The contractile responses to PGD2 may therefore be a result from its action on contractile prostanoid receptors, such as the TXA2 receptor (5, 6, 44) .
In summary, we have identified the gene and a cDNA for a mouse PGD receptor. Availability of the nucleotide and amino acid sequences of the PGD receptor will permit the identification of cells expressing this receptor and allow elucidation of the role for PGD2 in physiological and pathological conditions.
